B7-H3/CD276: An Emerging Cancer Immunotherapy

Front Immunol. 2021 Jul 19:12:701006. doi: 10.3389/fimmu.2021.701006.

Wu-Tong Zhou ¹, Wei-Lin Jin ¹ ²

Affiliations

1 Institute of Nano Biomedicine and Engineering, Shanghai Engineering Center for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai, China.
2 Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, Lanzhou, China.

PMID: 34349762 DOI: 10.3389/fimmu.2021.701006

Abstract

Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among Cancer treatments and points out a new direction for Cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target for Cancer Immunotherapy because it is overexpressed in tumor tissues while showing limited expression in normal tissues and participating in tumor microenvironment (TME) shaping and development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Herein, we present the expression and biological function of B7-H3 in distinct Cancer and normal cells, as well as B7-H3-mediated signal pathways in Cancer cells and B7-H3-based tumor immunotherapy strategies. This review provides a comprehensive overview that encompasses B7-H3's role in TME to its potential as a target in Cancer Immunotherapy.

Keywords

B7-H3/CD276; cancer immunotherapy; immune checkpoint; tumor immunology; tumor microenvironment.

Name
Email *

	Sorry, but the email address you supplied was invalid.